What the business is, and whether it's a good one at a fair price.
Operates a chain of 63+ eye care hospitals across India, supported by 250+ doctors, offering ophthalmology services such as consultations, diagnostics, laser treatments and eye surgeries to patients. In FY26, revenue reached ₹470.87 cr (up 18.6% YoY from ₹397.15 cr) with net profit of ₹70.10 cr and EBITDA margin of 32.1%. Other operating expenses form the largest cost line at 39.7% of revenue, followed by employee costs at 19.5%, consistent with a labour-intensive hospital model. Capex runs at 20.9% of revenue, supporting the addition of new centres and equipment. The Board declared total dividends of ₹7 per share for FY26 (interim ₹3 plus final ₹4) and raised ₹70 cr via a preferential issue to its holding company. A scheme to merge the listed company into its parent Dr. Agarwal's Health Care Limited, which runs 288 Indian facilities across 14 states and 5 UTs plus 19 facilities in Africa and already owns 72.67%, was approved by shareholders and creditors in July 2026, pending NCLT sanction.
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from DR. AGARWAL'S EYE HOSP L's filed financials and exchange disclosures
DR. AGARWAL'S EYE HOSP L is a Healthcare Services company listed on NSE and BSE, trading under the symbol DRAGARWQ.
Yes. Over the trailing twelve months DR. AGARWAL'S EYE HOSP L reported a net profit of ₹70 Cr on revenue of ₹471 Cr.
Yes. The dividend yield is 0.12% at the current price. It paid out 4% of its profit as dividend in FY26.
No. Debt stands at 0.24× equity, and it carries net debt of ₹75 Cr. That is lower than 52% of its 24 Hospital peers.
On trailing P/E, DR. AGARWAL'S EYE HOSP L ranks 13 of 30 in Hospital — cheaper than 59% of them, against an industry median of 47.3×. This is a position, not a valuation judgement.
On a typical session DR. AGARWAL'S EYE HOSP L moves 1.02% — that is the median absolute close-to-close move across its last 100 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by DR. AGARWAL'S EYE HOSP L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
